Literature DB >> 18473928

Indoles and related compounds as cannabinoid ligands.

Clementina Manera1, Tiziano Tuccinardi, Adriano Martinelli.   

Abstract

The discovery of the endocannabinoid system has lead to great strides in research development. At present, two cannabinoid receptors, CB1R and CB2R, are known. They belong to Class A rhodopsin-like GPCRs, and possess a different tissue distribution. Many synthetic compounds have been synthesized and tested for their cannabinoid activity. A particular class among them, the aminoalkylindole derivatives (typified by WIN55212-2) are hypothesized to interact in a binding site different from the main cannabinoid agonists. In this review we report the main aminoalkylindole derivatives, and other compounds which are hypothesized to interact in the same binding site. Furthermore we analyze the pharmacological profiles, the mutagenesis data and the computational models that describe their interaction in the cannabinoid receptors, evaluating the most important aspects for their activity and selectivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473928     DOI: 10.2174/138955708783955935

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  14 in total

1.  Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.

Authors:  Torbjörn U C Järbe; Hongfen Deng; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

Review 3.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

4.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

5.  Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

6.  AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Kateland R Antonazzo; Michael T Wallgren; Ricardo A Cortes; Purvi R Patel; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2015-06-23       Impact factor: 4.030

7.  1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Authors:  Jenny L Wiley; Julie A Marusich; Billy R Martin; John W Huffman
Journal:  Drug Alcohol Depend       Date:  2011-11-27       Impact factor: 4.492

Review 8.  CB₂: therapeutic target-in-waiting.

Authors:  Brady K Atwood; Alex Straiker; Ken Mackie
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-12-09       Impact factor: 5.067

Review 9.  Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.

Authors:  Jenny L Wiley; Julie A Marusich; John W Huffman
Journal:  Life Sci       Date:  2013-09-23       Impact factor: 5.037

10.  Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Authors:  Maheswari Rajasekaran; Lisa K Brents; Lirit N Franks; Jeffery H Moran; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2013-03-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.